A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Charles Lopez, MD
Oregon Health and Science University
Principal Investigator - J. Marc Pipas, MD
Dartmouth-Hitchcock Medical Center
Principal Investigator - Nathan Bahary, MD
University of Pittsburgh
Principal Investigator - Peter J O'Dwyer, MD
University of Pennsylvania
Principal Investigator - Smitha Krishnamurthi, MD
University Hospitals of Cleveland, Case Comprehensive Cancer Center
Principal Investigator - Vincent J Picozzi, MD, PhD
Virginia Mason Hospital/Medical Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Stanford University School of Medicine
Stanford, California, United States
- Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
- University Hospitals of Cleveland, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
- Oregon Health Sciences University (ohsu)
Portland, Oregon, United States
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
- University of Pittsburgh
Pittsburgh, Pennsylvania, United States
- Virginia Mason Medical Center
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2008
- Primary completion
- 31 May 2014
- Completion
- 30 Jun 2014
- Last update posted
- 6 Aug 2014
- Registered enrollment
- 50
- Registry id
- NCT01181245
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.